Our aim was to determine the levels of human urotensin-II (hU-II) in the plasma of migraine patients and controls, to ascertain if there were a difference in the pathogenesis of migraine. A total of 27 patients who suffer from migraines and 27 controls were included in the study. Venous blood samples were drawn twice both from migraine patients and controls to measure hU-II plasma levels. The average levels of hU-II during migraine episode, between episodes, and controls were found to be 0.483, 0.493, and 0.737 pg/mL, respectively. The levels of hU-II in the controls were higher significantly. When comparisons were made according to sex, age groups, and types and durations of migraine, there was no significant difference in the levels of hU-II in the patients. The low levels of hU-II in the plasma of migraine patients compared with controls may be an indicator of its role in the pathogenesis.
Mack KJEpisodic and chronic migraine in children. Semin Neurol. 2006;26:223-231.
2.
Mascia A., Afra J., Schoenen J.Dopamine and migraine: a review of pharmacological, biochemical, neurophysiological, and therapeutic data. Cephalalgia. 1998;18:174-182.
Janig W.Relationship between pain and autonomic phenomena in headache and other pain conditions. Cephalalgia. 2003;23:43-48.
5.
Sanchez del Rio M., Alvarez Linera J.Functional neuroimaging of headaches. Lancet Neurol. 2004;3:645-651.
6.
Coulouarn Y. , Jegou S., Tostivint H., et al. Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursor. FEBS Lett. 1999;457:28-32.
7.
Pearson D., Shively JE, Clark BR, et al. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci U S A. 1980;77:5021-5024.
8.
Ong KL, Lam KS, Cheung BMUrotensin II: its function in health and its role in disease. Cardiovasc Drugs Ther. 2005;19: 65-75.
9.
Carotenuto A. , Grieco P., Novellino E., Rovero P.Urotensin-II receptor peptide agonists. Med Res Rev. 2004;24:577-588.
10.
Watson A., May CNUrotensin II, a novel peptide in central and peripheral cardiovascular control . Peptides. 2004;25:1759-1766.
11.
Gartlon JE, Ashmeade T., Duxon M., et al. Urotensin-II, a neuropeptide ligand for GPR14, induces c-fos in the rat brain. Eur J Pharmacol. 2004;493:95-98.
12.
Yoshimoto T. , Matsushita M., Hirata Y.Role of urotensin II in peripheral tissue as an autocrine/paracrine growth factor. Peptides. 2004;25:1775-1781.
13.
Russell FDEmerging roles of urotensin-II in cardiovascular disease. Pharmacol Ther. 2004;103:223-243.
14.
Headache Classification Subcommittee of the International Headache Society.The international classification of headache disorders: 2nd ed. Cephalalgia. 2004;24(suppl 1):S9-S160.
15.
Pietrobon D. , Striessnig J.Neurobiology of migraine. Nat Rev Neurosci. 2003;4:386-398.
16.
Olesen J.Cerebral and extracranial circulatory disturbances in migraine: pathophysiological implications. Cerebrovasc Brain Metab Rev. 1991;3:1-28.
17.
Zhang AY, Chen YF, Zhang DX, et al. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol. 2003;285:792-798.
18.
Maguire JJ, Davenport APIs urotensin-II the new endothelin? Br J Pharmacol. 2002;137:579-588.
19.
Juhasz G., Zsombok T., Modos EA, et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain. 2003;106:461-470.
20.
Welch KMConcepts of headache pathogenesis: insights into mechanisms of chronicity and new drug targets. Neurol Sci. 2003;24(suppl 2):S149-S153.
21.
Martinez F. , Castillo J., Pardo J., et al. Catecholamine levels in plasma and CSF in migraine. J Neurol Neurosurg Psychiatry. 1993;56:1119-1121.
22.
Hsu LK, Crisp AH, Kalucy RS, et al. Early morning migraine. Nocturnal plasma levels of catecholamines, tryptophan, glucose, and free fatty acids and sleep encephalographs. Lancet. 1977; 1:447-451.
23.
Føg-Moller F. , Genefke IK, Bryndum B.Changes in concentration of catecholamines in blood during spontaneous migraine attacks. In: Grene H, ed. Current Concepts in Migraine Research. New York: Raven Press; 1978:115-119.
24.
Watson AM, Lambert GW, Smith KJ, May CNUrotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension. 2003;42:373-379.
25.
Gartlon J., Parker F., Harrison DC, et al. Central effects of urotensin-II following ICV administration in rats. Psychopharmacology. 2001;155:426-433.
26.
Matsumoto Y. , Abe M., Watanabe T., et al. Intracerebroventricular administration of urotensin II promotes anxiogenic-like behaviors in rodents. Neurosci Lett. 2004;358:99-102.
